Claims for Patent: 10,526,656

Summary for Patent: 10,526,656

Title:	Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
Abstract:	The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene TMSB15A is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene TMSB15A and optionally one or more further marker genes selected from DMBT1, KIAA1 T99, DPP6, SLC51 B, NUDT1 1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR1 10, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1 B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined. The invention also relates to an in vitro method of diagnosing stable COPD or assessing the susceptibility of a subject to develop stable COPD, wherein the expression of TMSB15A and optionally one or more further marker genes selected from DMBT1, KIAA1 199, DPP6, SLC51 B, NUDT1 1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR1 10, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1 B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined. Furthermore, the invention relates to the use of primers for transcripts of the aforementioned marker genes, the use of nucleic acid probes to transcripts of these marker genes, the use of microarrays comprising nucleic acid probes to transcripts of these marker genes, and the use of antibodies against the proteins expressed from these marker genes in corresponding in vitro methods. In vitro methods of monitoring the progression of COPD are also provided, in which the expression of marker genes according to the invention is determined.
Inventor(s):	Ziesche; Rolf (Neusiedl am See, AT)
Assignee:	Transgenion--International Institute for Regenerative Translational Medicine GmbH (Vienna, AT)
Application Number:	15/316,202
Patent Claims:	1. A method of treating chronic obstructive pulmonary disease (COPD), in a human subject that is prone to develop progressive COPD involving the appearance of irreversible lung damage, the method comprising: a) testing a lung tissue sample obtained from the human subject to determine the level of RNA expression of the gene TMSB15A; b) comparing the level of RNA expression of TMSB15A in the lung tissue sample from the human subject to a control RNA expression level of TMSB15A in a healthy human subject; c) identifying the human subject as being prone to develop progressive COPD based on detecting a decrease in the level of RNA expression of TMSB15A in the lung tissue sample from the subject as compared to the control RNA expression level of TMSB15A; and d) administering a drug against COPD to the human subject identified in step c). 2. The method of claim 1, the drug against COPD being bitolterol, carbuterol, fenoterol, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, levosalbutamol, terbutaline, tulobuterol, arformoterol, bambuterol, clenbuterol, formoterol, olodaterol, salmeterol, indacaterol, beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone, aclidinium bromide, glycopyrronium bromide, ipratropium bromide, oxitropium bromide, tiotropium bromide, cromoglicate, nedocromil, acefylline, ambuphylline, bamifylline, doxofylline, enprofylline, etamiphylline, proxyphylline, theobromine, theophylline, aminophylline, choline theophyllinate, montelukast, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, ibudilast, roflumilast, amlexanox, eprozinol, fenspiride, omalizumab, epinephrine, hexoprenaline, isoprenaline, isoproterenol, orciprenaline, metaproterenol, atropine, or a pharmaceutically acceptable salt of any of the aforementioned agents, or any combination thereof. 3. The method of claim 1, the drug against COPD being roflumilast. 4. A method of treating or preventing chronic obstructive pulmonary disease (COPD), the method comprising administering a drug against COPD to a human subject that has been identified as suffering from stable COPD or as being prone to suffer from stable COPD, the method comprising the steps of: a) testing a human lung tissue sample obtained from the human subject to determine the level of RNA expression of the gene TMSB15A; b) comparing the level of RNA expression of TMSB15A in the lung tissue sample from the human subject to a control RNA expression level of TMSB15A in a healthy human subject, a decrease in the level of RNA expression of TMSB15A in the lung tissue sample from the human subject as compared to the control RNA expression level of TMSB15A being indicative of stable COPD or a proneness to stable COPD; c) identifying the human subject as suffering from stable COPD or as being prone to suffer from stable COPD based on detecting a decrease in the level of RNA expression of TMSB15A in the lung tissue sample from the human subject as compared to the control RNA expression level of TMSB15A; and d) administering a drug against COPD to the subject identified in step c). 5. The method of claim 4, the drug against COPD being bitolterol, carbuterol, fenoterol, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, levosalbutamol, terbutaline, tulobuterol, arformoterol, bambuterol, clenbuterol, formoterol, olodaterol, salmeterol, indacaterol, beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone, aclidinium bromide, glycopyrronium bromide, ipratropium bromide, oxitropium bromide, tiotropium bromide, cromoglicate, nedocromil, acefylline, ambuphylline, bamifylline, doxofylline, enprofylline, etamiphylline, proxyphylline, theobromine, theophylline, aminophylline, choline theophyllinate, montelukast, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, ibudilast, roflumilast, amlexanox, eprozinol, fenspiride, omalizumab, epinephrine, hexoprenaline, isoprenaline, isoproterenol, orciprenaline, metaproterenol, atropine, or a pharmaceutically acceptable salt of any of the aforementioned agents, or any combination thereof. 6. The method of claim 1, further comprising: a) testing the level of RNA expression of one or more of DMBT1, KIAA1199, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 or GHRL in the lung tissue sample obtained from the human subject; b) comparing the level of RNA expression of the one or more genes tested in step a) to a control RNA expression level of the one or more genes in a healthy human subject; and c) an increase in the level of RNA expression of DMBT1, KIAA1199, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject as compared to the control RNA expression level of the one or more gene(s) is indicative of a proneness to develop progressive COPD, and d) a decrease in the level of RNA expression of TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject as compared to the control RNA expression level of the one or more gene(s) is indicative of a proneness to develop progressive COPD. 7. The method of claim 6, comprising testing the lung tissue sample of the human subject to determine the level of RNA expression of DMBT1 and KIAA1199. 8. The method of claim 6, comprising testing the human lung tissue sample to determine the level of RNA expression of DMBT1, KIAA1199 and at least one of FGG, CYP1A1, CEACAM5, CTHRC1, NTRK2, RASGRF2, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, DPP6, SLC51B or NUDT11. 9. The method of claim 6, comprising testing the human lung tissue sample to determine that the human subject is prone to develop progressive COPD involving the appearance of irreversible lung damage if the level of RNA expression of a majority of the number of genes tested is altered in the sense that (i) the level of RNA expression of DMBT1, KIAA1199, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject is increased as compared to the control RNA expression level of the one or more gene(s) and (ii) the level of RNA expression of TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject is decreased as compared to the control RNA expression level of the one or more gene(s). 10. The method of claim 6, comprising testing the human lung tissue sample to determine that the human subject is prone to develop progressive COPD involving the appearance of irreversible lung damage if the level of RNA expression of a majority of the number of genes tested is altered in the sense that (i) the level of RNA expression of DMBT1, KIAA1199, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject is at least 3-fold increased as compared to the control RNA expression level of the one or more gene(s) and (ii) the level of RNA expression of TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject is at least 3-fold decreased as compared to the control RNA expression level of the one or more gene(s). 11. The method of claim 6, comprising testing the human lung tissue sample to determine that the human subject is prone to develop progressive COPD involving the appearance of irreversible lung damage if the level of RNA expression of at least 70% of the number of genes tested is altered in the sense that (i) the level of RNA expression of DMBT1, KIAA1199, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject is increased as compared to the control RNA expression level of the one or more gene(s) and (ii) the level of RNA expression of TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject is decreased as compared to the control RNA expression level of the one or more gene(s). 12. The method of claim 6, comprising testing the human lung tissue sample to determine that the human subject is prone to develop progressive COPD involving the appearance of irreversible lung damage if the level of RNA expression of at least 70% of the number of genes tested is altered in the sense that (i) the level of RNA expression of DMBT1, KIAA1199, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject is at least 3-fold increased as compared to the control RNA expression level of the one or more gene(s) and (ii) the level of RNA expression of TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject is at least 3-fold decreased as compared to the control RNA expression level of the one or more gene(s). 13. The method of claim 1, the tested human lung tissue sample being a transbronchial lung biopsy lung tissue sample or a bronchoalveolar lavage lung tissue sample. 14. The method of claim 1, the level of RNA expression being determined using a quantitative reverse transcriptase polymerase chain reaction or a microarray. 15. The method of claim 4, comprising: a) testing the human lung tissue sample to determine the level of RNA expression of one or more of DMBT1, KIAA1199, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1, or GHRL in the lung tissue sample obtained from the human subject; b) comparing the level of RNA expression of the one or more genes to a control RNA expression level of the one or more gene(s) in a healthy human subject; and c) testing the human lung tissue sample to determine an increase in the level of RNA expression of DMBT1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject as compared to the control RNA expression level of the one or more gene(s) being indicative of stable COPD or a proneness to stable COPD, and d) a decrease in the level of RNA expression of TMSB15A, KIAA1199, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject as compared to the control RNA expression level of the one or more gene(s) being indicative of stable COPD or a proneness to stable COPD. 16. The method of claim 15, comprising testing the human lung tissue sample to determine if the human subject suffers from stable COPD or is prone to suffer from stable COPD if the level of RNA expression of a majority of the number of genes tested is altered in the sense that (i) the level of RNA expression of DMBT1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject is increased as compared to the control RNA expression level of the gene or genes so tested and (ii) the level of RNA expression of KIAA1199, TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject is decreased as compared to the control RNA expression level of the gene or genes tested. 17. The method of claim 15, comprising testing the human lung tissue sample to determine if the human subject suffers from stable COPD or is prone to suffer from stable COPD if the level of RNA expression of at least 70% of the number of genes tested is altered in the sense that (i) the level of RNA expression of DMBT1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, FGG, CEACAM5, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, NTRK2 and/or COMP in the lung tissue sample from the human subject is at least 3-fold increased as compared to the control RNA expression level of the gene or genes tested and (ii) the level of RNA expression of KIAA1199, TMSB15A, DPP6, SLC51B, NUDT11, PLA1A, HYAL2, CST6, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and/or GHRL in the lung tissue sample from the human subject is at least 3-fold decreased as compared to the control RNA expression level of the one or more genes tested. 18. The method of claim 4, the lung tissue sample obtained from the human subject being a transbronchial lung biopsy lung tissue sample or a bronchoalveolar lavage lung tissue sample. 19. The method of claim 4, the level of RNA expression being determined using a quantitative reverse transcriptase polymerase chain reaction or a microarray.

Details for Patent 10,526,656

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003		2034-06-05
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018		2034-06-05